712 North Inc. develops **neuroprotective drugs for patients with Alzheimer’s disease** and other forms of dementia. The company was founded at **UCSF** around a **novel, proprietary mitochondrial target protease** crucial for neuronal survival. The target is **highly validated and supported by in vivo data**. We have identified the target by studying a genetic orphan disease of childhood blindness with the name of **Autosomal Dominant Optic Atrophy (ADOA)**. We **differentiate ourselves** from all competitors in the field in that 712 North leverages the **orphan indication as fast-to-market strategy**. We strongly believe that the **genetically defined patient group** and **orphan drug status** can accelerate clinical proof of concept for neuroprotective drugs. Our **platform technology** built around the target allows us also to pursue discovery programs for **other age-related diseases**, such as cancer.

**LEADERSHIP**

**Marcel V. Alavi, PhD, Founder**, is a scientist-entrepreneur and the original inventor of the technology. He has studied ADOA for more than 12 years, after which he founded 712 North to translate his research into therapies.

**TIMELINES**

**FINANCIALS**

We are currently seeking seed funding to consolidate our patents, close licensing deals and advance the drug development programs. We estimate that we will require in total $10M to $15M to be ready for first-in-human trials within the next 4 to 5 years. Clinical proof-of-concept in the orphan indication is projected at $15M to $35M and can be accomplished within 18 months.

---

THIS EXECUTIVE SUMMARY DOES NOT CONSTITUTE AN OFFER TO SELL, OR A SOLICITATION OF AN OFFER TO BUY, ANY SECURITIES OF 712 NORTH INC. (THE “COMPANY”) TO ANYONE IN ANY STATE OR IN ANY JURISDICTION. ANY OFFER, SALE OR ISSUANCE OF ANY SECURITIES OF THE COMPANY SHALL ONLY BE MADE PURSUANT TO A DEFINITIVE PURCHASE AGREEMENT ENTERED INTO BETWEEN THE PURCHASER AND THE COMPANY. ANY OFFER TO INVEST IN THE SECURITIES OF THE COMPANY, AND ANY SUBSEQUENT SALE OF THE COMPANY’S SECURITIES, HAS NOT BEEN, AND WILL NOT BE, REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES ACT, AND ANY SECURITIES OF THE COMPANY WILL ONLY BE OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SUCH ACTS.